Background: Persistent unresolved inflammation results in a number of pathologic respiratory diseases including asthma. Lipidomics is the most important branch of metabolomics that involves the identification and quantitative measurement of lipids of a biological object. Our study aims to assess the coorelations between pro-inflammatory mediators, pro-resolvant lipid mediators and endocannabinoids and asthma clinical and spirometric features.

Methods: Cross sectional, mono-centric study, enrolling adult patients with stable asthma  from November 2020 to November 2021. The mesurement of lipid mediators was done in plasma and induced sputum using liquid chromatography coupled to mass spectometry (LC-MS-MS).

Results: 41 patients were enrolled (mean age 47.45 ± 5.51 years ; sex ratio 0,52). Duration of asthma was negatively correlated to plasmatic 2-arachidonylglycerol and prostaglandin D2. Asthma control was positively correlated to 6-keto prostaglandin F1a in sputum and Alpha linolenicacid, palmitoylethanolamide and oleoylethanolamide in plasma. FEV1 was negatively correlated to 7.17 OH DPA in plasma and Tiffeneau-index was negatively correlated to plasmatic prostalandin D2. The usage of high doses of inhaled glucocorticoids was correlated with lower rates of leukotrien C4 and F4 and lipoxin A4 in plasma wheras high doses of bronchodilatators was correlated with lower leukotrien C4 and lipoxin A4 in sputum.

Conclusion: Inflammatory lipi dmediators, resolving lipid mediators and endocannabinoid rates seem to impact asthma characteristics and may provide a better undrestanding of the pathogeny of the disease.